Sarepta Therapeutics Inc

NASDAQ:SRPT  
130.19
+1.81 (+1.41%)
7:48:46 PM EDT: $130.33 +0.14 (+0.11%)
Products, Regulatory, Earnings Announcements

Sarepta Announces Results From Ongoing Momentum Study, Phase 2 Clinical Trial Of SRP-5051

Published: 12/07/2020 14:01 GMT
Sarepta Therapeutics Inc (SRPT) - Sarepta Therapeutics Inc - Announced Results From Ongoing Momentum Study, a Phase 2 Clinical Trial of Srp-5051.
Sarepta Therapeutics Inc - Srp-5051 Was Generally Well-tolerated Across All Doses Studied, With No Clinical Or Laboratory Findings Reported.
Sarepta Therapeutics Inc - Results Support Continued Dose Escalation of Srp-5051 and Further Clinical Development.
Revenue is expected to be $242.4 Million
Adjusted EPS is expected to be -$1.33

Next Quarter Revenue Guidance is expected to be $258.46 Million
Next Quarter EPS Guidance is expected to be -$1.56

More details on our Analysts Page.